Toronto researchers have shown that targeting SIRPA disrupts its interaction with CD47 on macrophages and could help prevent engraftment of AML stem cells. The data provide validation for a SIRPA-Fc fusion protein being developed by Trillium that antagonizes the SIRPA-CD47 interaction.